CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Amgen Inc. (AMGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Amgen Inc. (AMGN)

Biological Products, (No Diagnostic Substances) · market cap $219.9B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Amgen (AMGN) is a Thousand Oaks, CA biopharma with about 31,500 employees and a market cap near $240B. Our database tracks a broad pipeline led by tarlatamab (DLL3xCD3 BiTE, Phase 3 in small cell lung cancer; orphan, fast-track and breakthrough designations), plus maridebart cafraglutide in Phase 3 for T2DM and obesity. The next two high-importance catalysts in our calendar are ABP 234 (Phase 3, est. 2026-12-14) and maridebart cafraglutide (Phase 3, est. 2027-01-21).
The catalyst path
  • 2026-11-30 (est.)Phase 2 · Anvumetostatimp 7/10
  • 2026-12-14 (est.)Phase 3 · ABP 234imp 9/10
  • 2026-12-30 (est.)Phase 2 · Blinatumomabimp 7/10
  • 2027-01-06 (est.)Phase 2 · AMG 732imp 7/10
  • 2027-01-15 (est.)Phase 2 · pegfilgrastimimp 7/10
  • 2027-01-21 (est.)Phase 3 · Maridebart cafraglutideimp 9/10
  • 2027-02-01 (est.)Phase 2 · Autologous Stem Cell Transplant (ASCT)imp 7/10
  • 2027-03-15 (est.)Phase 2 · Romosozumab Prefilled Syringeimp 7/10
Pipeline
AssetPhaseIndication
Rozibafusp AlfaPhase 2Systemic Lupus Erythematosus (SLE)
LumakrasApprovedKRAS G12C NSCLC
TarlatamabPhase 3Small Cell Lung Cancer
AMG 509Phase 1Prostate Cancer
Etanercept LiquidPhase 3Rheumatoid Arthritis
Erenumab-aooe (EREN) s.c. administered every four weeks for a total of five treatmentsPhase 2Temporomandibular Disorder
Vinblastine sulfatePhase 2HIV Infections
PEG asparaginasePhase 2Lymphoblastic Leukemia
romosozumab HCP administration with PFSPhase 3Post-Menopausal Osteoporosis
bemarituzumab, trifluridine/tipiracilPhase 2Metastatic Gastro-esophageal Adenocarcinoma
AMG 102 and erlotinibPhase 2Carcinoma, Non-Small-Cell Lung
AnvumetostatPhase 2Advanced MTAP-null Solid Tumors
bemarituzumab, irinotecanPhase 2Metastatic Gastro-esophageal Adenocarcinoma
Panitumumab + FOLFOX (DP)Phase 2Metastatic Colorectal Cancer
Omitted Vincristine+Dexamethasone pulsesPhase 3Leukemia, Acute Lymphoblastic
MetoprololPhase 3Cardiovascular Disease
Inotuzumab Ozogamicin+Standard Maintenance TherapyPhase 3Leukemia, Acute Lymphoblastic
NitroglycerinPhase 3Cardiovascular Disease
Evolocumab AI/penPhase 3Primary Hypercholesterolemia
6-tioguanine+Standard Maintenance TherapyPhase 3Leukemia, Acute Lymphoblastic
Price & technical context
3-month
+10.6%
6-month
+45.1%
12-month
+40.0%
52-wk range
$313.85–$478.48
vs 50-day MA
+10.5%
vs 200-day MA
+23.3%
Realized vol
28.7%
Max drawdown
-21.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for AMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.